Telix Pharmaceuticals Ltd. - news published 32 - readings 170

BACK
Telix Pharmaceuticals Ltd.

Telix Pharmaceuticals Ltd.

FDA Approves New Prostate Cancer Imaging Agent Gozellix® (Form 6-K)

FDA Approves New Prostate Cancer Imaging Agent Gozellix® Melbourne (Australia) and Indianapolis, IN (U.S.A.) - 21 March 2025. Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Gozellix® (TLX007-CDx, kit for the preparation o ...

Continue reading
21.03.2025
Telix Pharmaceuticals Ltd.

Telix Pharmaceuticals Ltd.

Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in The Netherlands

Melbourne (Australia) | 18 March 2025 Telix today announces that its prostate cancer PET [1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by MEB [2] for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, a broad clinical la ...

Continue reading
18.03.2025
Telix Pharmaceuticals Ltd.

Telix Pharmaceuticals Ltd.

Telix Completes Acquisition of FAP-targeting Theranostic Candidates (Form 6-K)

Telix Completes Acquisition of FAP-targeting Theranostic Candidates Melbourne (Australia) and Indianapolis, IN (U.S.A.) - 12 March 2025. Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has completed the transaction to expand its theranostic pipeline with new candidates targeting Fibroblast Activation Protein (FAP), one of the m ...

Continue reading
12.03.2025